Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer

Martin J. Edelman, Frederick J Meyers, Tim Grennan, Jun Lauder, James Doroshow

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

No effective therapy has been demonstrated for hormone refractory prostate cancer (HRPC). Pyrazine diazohydroxide (PZDH) is a novel antineoplastic agent with a broad range of activity in preclinical studies and a moderate toxicity profile in Phase I trials. We undertook a Phase II study of PZDH in HRPC utilizing decline in PSA as the primary end point. Fifteen patients were enrolled, median age of 70 (55-86), median pretherapy PSA 206 ng/ml (range 42-10,000). Four patients were African American. Sites of disease: bone only 7, soft tissue only 2, both 6. All were evaluable for toxicity and response. PZDH was administered at 250 mg/m2 IV every three weeks. The median number of cycles administered was two (range 1-6). Toxicity was mild, with only one patient manifesting serious (grade 3-4) toxicity. Unfortunately, activity was minimal with only a single patient demonstrating a > 75% decline in PSA. As this patient's PSA began to rise almost immediately the response was considered transient and not felt to justify pursuing a second stage of the trial. Supporting this conclusion was the disappointing median survival of 220 days. in summary, we conclude that PZDH, while well tolerated at this dose and schedule has only minimal activity in HRPC.

Original languageEnglish (US)
Pages (from-to)179-182
Number of pages4
JournalInvestigational New Drugs
Volume16
Issue number2
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

pyrazine-2-diazohydroxide
Pyrazines
Androgens
Prostatic Neoplasms
Hormones
Bone Diseases
African Americans
Antineoplastic Agents
Appointments and Schedules
Survival

Keywords

  • Hormone refractory
  • Phase II trial
  • Prostate cancer
  • Pyrazine diazohydroxide

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer. / Edelman, Martin J.; Meyers, Frederick J; Grennan, Tim; Lauder, Jun; Doroshow, James.

In: Investigational New Drugs, Vol. 16, No. 2, 1998, p. 179-182.

Research output: Contribution to journalArticle

Edelman, Martin J. ; Meyers, Frederick J ; Grennan, Tim ; Lauder, Jun ; Doroshow, James. / Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer. In: Investigational New Drugs. 1998 ; Vol. 16, No. 2. pp. 179-182.
@article{8487b4a017614bfaa9dd820d296e9def,
title = "Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer",
abstract = "No effective therapy has been demonstrated for hormone refractory prostate cancer (HRPC). Pyrazine diazohydroxide (PZDH) is a novel antineoplastic agent with a broad range of activity in preclinical studies and a moderate toxicity profile in Phase I trials. We undertook a Phase II study of PZDH in HRPC utilizing decline in PSA as the primary end point. Fifteen patients were enrolled, median age of 70 (55-86), median pretherapy PSA 206 ng/ml (range 42-10,000). Four patients were African American. Sites of disease: bone only 7, soft tissue only 2, both 6. All were evaluable for toxicity and response. PZDH was administered at 250 mg/m2 IV every three weeks. The median number of cycles administered was two (range 1-6). Toxicity was mild, with only one patient manifesting serious (grade 3-4) toxicity. Unfortunately, activity was minimal with only a single patient demonstrating a > 75{\%} decline in PSA. As this patient's PSA began to rise almost immediately the response was considered transient and not felt to justify pursuing a second stage of the trial. Supporting this conclusion was the disappointing median survival of 220 days. in summary, we conclude that PZDH, while well tolerated at this dose and schedule has only minimal activity in HRPC.",
keywords = "Hormone refractory, Phase II trial, Prostate cancer, Pyrazine diazohydroxide",
author = "Edelman, {Martin J.} and Meyers, {Frederick J} and Tim Grennan and Jun Lauder and James Doroshow",
year = "1998",
doi = "10.1023/A:1006097109088",
language = "English (US)",
volume = "16",
pages = "179--182",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer

AU - Edelman, Martin J.

AU - Meyers, Frederick J

AU - Grennan, Tim

AU - Lauder, Jun

AU - Doroshow, James

PY - 1998

Y1 - 1998

N2 - No effective therapy has been demonstrated for hormone refractory prostate cancer (HRPC). Pyrazine diazohydroxide (PZDH) is a novel antineoplastic agent with a broad range of activity in preclinical studies and a moderate toxicity profile in Phase I trials. We undertook a Phase II study of PZDH in HRPC utilizing decline in PSA as the primary end point. Fifteen patients were enrolled, median age of 70 (55-86), median pretherapy PSA 206 ng/ml (range 42-10,000). Four patients were African American. Sites of disease: bone only 7, soft tissue only 2, both 6. All were evaluable for toxicity and response. PZDH was administered at 250 mg/m2 IV every three weeks. The median number of cycles administered was two (range 1-6). Toxicity was mild, with only one patient manifesting serious (grade 3-4) toxicity. Unfortunately, activity was minimal with only a single patient demonstrating a > 75% decline in PSA. As this patient's PSA began to rise almost immediately the response was considered transient and not felt to justify pursuing a second stage of the trial. Supporting this conclusion was the disappointing median survival of 220 days. in summary, we conclude that PZDH, while well tolerated at this dose and schedule has only minimal activity in HRPC.

AB - No effective therapy has been demonstrated for hormone refractory prostate cancer (HRPC). Pyrazine diazohydroxide (PZDH) is a novel antineoplastic agent with a broad range of activity in preclinical studies and a moderate toxicity profile in Phase I trials. We undertook a Phase II study of PZDH in HRPC utilizing decline in PSA as the primary end point. Fifteen patients were enrolled, median age of 70 (55-86), median pretherapy PSA 206 ng/ml (range 42-10,000). Four patients were African American. Sites of disease: bone only 7, soft tissue only 2, both 6. All were evaluable for toxicity and response. PZDH was administered at 250 mg/m2 IV every three weeks. The median number of cycles administered was two (range 1-6). Toxicity was mild, with only one patient manifesting serious (grade 3-4) toxicity. Unfortunately, activity was minimal with only a single patient demonstrating a > 75% decline in PSA. As this patient's PSA began to rise almost immediately the response was considered transient and not felt to justify pursuing a second stage of the trial. Supporting this conclusion was the disappointing median survival of 220 days. in summary, we conclude that PZDH, while well tolerated at this dose and schedule has only minimal activity in HRPC.

KW - Hormone refractory

KW - Phase II trial

KW - Prostate cancer

KW - Pyrazine diazohydroxide

UR - http://www.scopus.com/inward/record.url?scp=0031761823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031761823&partnerID=8YFLogxK

U2 - 10.1023/A:1006097109088

DO - 10.1023/A:1006097109088

M3 - Article

C2 - 9848583

AN - SCOPUS:0031761823

VL - 16

SP - 179

EP - 182

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -